Congress Removes Hemp THC Protections, Putting Medicaid CBD Coverage in Doubt

Congressional leaders have eliminated key language from a major spending bill that would have temporarily delayed a federal ban on hemp-derived THC products, raising new uncertainty for the U.S. hemp industry and the future of Medicaid coverage for CBD treatments. The removal of these protections, reported by MJBizDaily, comes just as President Donald Trump had promised to extend health insurance coverage to non-intoxicating CBD products, a move that now faces significant delays due to the regulatory limbo

The $28 billion U.S. hemp sector has been on edge since November, when a government funding deal redefined hemp under federal law, effectively recriminalizing many popular hemp-derived THC products. Under new restrictions set to take effect in November, hemp-derived products must contain no more than 0.4 milligrams of THC per package, a threshold that advocates say would also criminalize a wide range of non-intoxicating CBD products. As the temporary spending package expires at the end of January, industry stakeholders are pushing Congress to include a delay in the ban within the next funding bill

Efforts to insert a reprieve for hemp THC products into the spending bill had initially made progress, with bipartisan support from lawmakers such as Rep. Jim Baird (R-IN) and Rep. Angie Craig (D-MN). However, MJBizDaily reports that opposition from the House Freedom Caucus, led by Rep. Andy Harris (R-MD)—the architect of the original ban—succeeded in stripping the delay from the bill. "As the days go on, we’re picking up more and more support in Congress and among other major policy players," said Jonathan Miller, general counsel for the U.S. Hemp Roundtable. "I’m cautiously optimistic we’re going to get an extension I feel like we have a lot of momentum to get one over the next several weeks before it’s crunch time for our farmers with their planting decisions."

The uncertainty is not limited to hemp producers. On December 18, President Trump and Centers for Medicare & Medicaid Services (CMMS) administrator Mehmet Oz announced plans to allow seniors to seek up to $500 in reimbursements for CBD products that meet local and state standards, possibly as soon as April. This initiative, championed by Florida billionaire Howard Kessler, could provide a significant boost to the CBD market if implemented. However, further details have yet to be released, and federal agencies remain hesitant to move forward without clear legislative guidance

The future of Medicaid and Medicare coverage for CBD now hinges on Congress’s willingness to revisit the classification of hemp-derived products and clarify their legal status. Industry advocates warn that unless lawmakers act to delay or revise the THC ban, both farmers and patients could face chaos and disruption. According to MJBizDaily, even agencies like the U.S. Department of Agriculture are waiting for congressional direction before taking further steps to support the industry

From the OG Lab newsroom perspective, Congress's decision to remove hemp THC protections highlights the volatility facing cannabis and hemp operators in the U.S. The outcome of ongoing legislative negotiations will not only determine the fate of CBD access for patients but could also reshape the legal landscape for the entire hemp sector. This is a pivotal moment for both the industry and consumers, and OG Lab will closely monitor the evolving policy debate